Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5770
Title: Development of reversible posterior leukoencephalopathy syndrome after cyclophosphamide treatment in a patient with lupus nephritis
Authors: Yildiz, S.
Güçlü, A.
Degirmenci, E.
Kiroglu, Y.
Yalçin, N.
Çobankara, V.
Topaloglu, M.
Erürker, Muammer
Keywords: Cyclophosphamide
Lupus nephritis
Reversible posterior leucoencephalopathy syndrome
Abstract: Renal involvement in systemic lupus erythematosus is a frequent and serious complication that significantly increases morbidity and mortality. Despite all studies and usage of new drugs, treatment of lupus nephritis continues to be a problem. Diffuse proliferative lupus nephritis has a poor prognosis and aggressive treatment must be undertaken. Cyclophosphamide is commonly used in treatment despite its side effects. Reversible posterior leucoencephalopathy syndrome is a clinico-radiological syndrome manifested by blood pressure elevation, headache, visual disturbances, confusion, seizures and sometimes focal neurological signs that can develop due to usage of cytotoxic drugs. We present a case of lupus nephritis in which reversible posterior leucoencephalopathy syndrome developed after intravenous cyclophosphamide administration and recovered spontaneously by symptomatic treatment in this article.
URI: https://hdl.handle.net/11499/5770
https://doi.org/10.5262/tndt.2011.1001.19
ISSN: 1300-7718
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
bd55f36b-020f-4bac-adcf-f97aa6e06994.pdf321.74 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

60
checked on Aug 24, 2024

Download(s)

20
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.